We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

02 Jun 2026 - 04 Jun 2026
17 Jun 2026 - 19 Jun 2026

Persistent Trichomoniasis Infection Found in Pregnant Women

By LabMedica International staff writers
Posted on 29 Aug 2018
Trichomoniasis is a very common sexually transmitted disease (STD). More...
It is caused by infection with a protozoan parasite called Trichomonas vaginalis. Although symptoms of the disease vary, most people who have the parasite cannot tell they are infected.

Trichomoniasis is the most common curable STD. In the USA, an estimated 3.7 million people have the infection. However, only about 30% develop any symptoms of trichomoniasis. Infection is more common in women than in men. Older women are more likely than younger women to have been infected with trichomoniasis.

Scientists at the Medical University of South Carolina (Charleston, SC, USA) determined the rate of persistent T. vaginalis infection among pregnant women post-treatment. Their secondary objective was to determine if oral multi-dose metronidazole was associated with fewer cases of persistent T. vaginalis compared to single dose treatment. The team carried out a retrospective cohort study of women diagnosed with genital T. vaginalis from 2008 to 2017. They calculated the rate of persistent trichomoniasis by dividing the number of positive Trichomonas tests collected ≥ 21 days post-treatment by the total number of women treated and retested.

The physicians reported that 542 women with 565 pregnancies were diagnosed with T. vaginalis infection. The majority of subjects were prescribed either single dose (n=352) or multi-dose metronidazole (n=74). Post-treatment Trichomonas tests were collected ≥ 21 days in 326 subjects and 44% (143) were positive. Rates of positive Trichomonas tests among women receiving single dose and multi-dose regimens were similar (45% versus 40%). Women who had ≥ 1 pregnancy affected by Trichomonas infection were more likely to have a positive test post-treatment. Obese women were less likely to have a positive test post-treatment.

The authors concluded that given high rates of positive Trichomonas tests and increased detection with nucleic acid amplification tests (NAATs); all pregnant women should be retested with NAATs around three weeks post-treatment. Further studies are needed to determine the most effective treatment of Trichomonas infection in pregnant women. The study was published on July 31, 2018, in the journal Sexually Transmitted Diseases.

Related Links:
Medical University of South Carolina


Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Online QC Software
Acusera 24•7
New
Automated Coagulation Analyzer
Hemolumi H6
Pipette Calibration System
Artel PCS®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The updated CRC screening guidance adds a stool RNA test and an updated stool DNA test to the menu of preferred options (image credit: Adobe Stock)

Updated Guidance Prioritizes Stool-Based Colorectal Cancer Screening Tests

Colorectal cancer is the second-leading cause of cancer death in the United States and claimed an estimated 55,000 lives in 2026. Incidence is rising among adults younger than 50, even as overall mortality... Read more

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.